Myokardia Inc (NASDAQ:MYOK) CEO Anastasios Gianakakos sold 5,000 shares of the stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $65.02, for a total value of $325,100.00. Following the completion of the sale, the chief executive officer now owns 90,864 shares of the company’s stock, valued at $5,907,977.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.
Anastasios Gianakakos also recently made the following trade(s):
- On Monday, November 4th, Anastasios Gianakakos sold 5,000 shares of Myokardia stock. The shares were sold at an average price of $59.07, for a total value of $295,350.00.
- On Wednesday, October 2nd, Anastasios Gianakakos sold 4,000 shares of Myokardia stock. The shares were sold at an average price of $52.28, for a total value of $209,120.00.
- On Wednesday, September 11th, Anastasios Gianakakos sold 1,000 shares of Myokardia stock. The shares were sold at an average price of $55.00, for a total value of $55,000.00.
Shares of NASDAQ:MYOK traded up $1.56 during mid-day trading on Wednesday, reaching $67.09. 318,766 shares of the stock were exchanged, compared to its average volume of 431,952. The company has a market cap of $3.01 billion, a P/E ratio of -38.12 and a beta of 2.07. Myokardia Inc has a one year low of $39.01 and a one year high of $66.44. The stock’s 50 day simple moving average is $58.71 and its 200-day simple moving average is $53.44.
A number of analysts recently issued reports on MYOK shares. Guggenheim started coverage on shares of Myokardia in a report on Thursday, September 19th. They set a “buy” rating on the stock. Cowen reaffirmed a “buy” rating and issued a $73.00 price target on shares of Myokardia in a research note on Monday, November 11th. ValuEngine cut shares of Myokardia from a “strong-buy” rating to a “buy” rating in a report on Tuesday. BidaskClub raised shares of Myokardia from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Wedbush raised their price objective on shares of Myokardia from $87.00 to $90.00 and gave the stock an “outperform” rating in a report on Thursday, August 8th. Two investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $76.89.
Institutional investors and hedge funds have recently modified their holdings of the company. Quadrant Capital Group LLC acquired a new stake in shares of Myokardia in the third quarter valued at approximately $33,000. Amundi Pioneer Asset Management Inc. acquired a new position in shares of Myokardia during the 1st quarter worth about $68,000. Aperio Group LLC bought a new position in shares of Myokardia in the 2nd quarter valued at about $92,000. Strs Ohio grew its holdings in shares of Myokardia by 440.0% in the 3rd quarter. Strs Ohio now owns 2,700 shares of the biotechnology company’s stock valued at $140,000 after acquiring an additional 2,200 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Myokardia by 39.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,803 shares of the biotechnology company’s stock valued at $141,000 after acquiring an additional 791 shares during the last quarter.
MyoKardia, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. Its lead product candidate is mavacamten, an orally administered small molecule, which is in Phase III clinical trial that is designed to reduce left ventricular contractility to alleviate the functional consequences and symptoms of obstructive hypertrophic cardiomyopathy (HCM) and prevent or reverse HCM progression, as well as in Phase II clinical trial for non-obstructive HCM.
Read More: Why are trading ranges significant?
Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.